Billionaires have long capitalized on America's love for convenient snacks and guilty pleasures. Stocks offering consumable dopamine hits feature prominently in portfolios from Warren Buffett to Bill Gates and Ray Dalio.
While it's easy to attribute gains in soda and fast-food stocks to unhealthy consumer habits—potentially threatened by the latest weight-loss drugs—analysts say these brands' diversification into healthier options will sustain them in an Ozempic-era future.
